Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
226 / 17.026
#1801

Re: Farmas USA

Que crees que la están bajando para asustar y meterse los fuertes?

#1803

Re: Farmas USA

Para los que estan dentro de ECYT; Un comentario en Twitter dice esto;

ECYT drifting lower with very low volumes, last 2 times than one day exploded overnite.

Saludos

#1804

Re: Farmas USA

Emitirán 125 mm de acciones adicionales. Yo pensaría bien el mantener.

#1805

Re: Farmas USA

eso son muuuuuchas acciones nuevas.
Con lo bien que pintaba......

#1807

Re: Farmas USA

Gracias. Pero no estoy en ECYT.

#1808

Re: Farmas USA

EXEL. La historia pasa por ser tremendamente parecida a la de ARNA, se la juegan a cara o cruz... sólo que en ASCO van con ocho monedas ;)

Exelixis (EXEL) is testing its drug cabozantinib in multiple types of cancer and some investors think the product can be a blockbuster someday. The company received an embarrassing setback last year when it misread signals from the FDA on the design of a study of prostate cancer patients. (See Exelixis Plunges as FDA Refuses to Sign Off on Drug Study.)

“We expect an extensive update on (cabozantinib) data,” Stifel Nicolaus analyst Joel Sendek says. He is looking for more details on studies of the drug for prostate, thyroid, and breast cancers, as well as melanoma and other conditions.

Read more: http://www.minyanville.com/business-news/politics-and-regulation/articles/asco-pfizer-johnson-2526-johnson-ariad/5/15/2012/id/41024#ixzz1uyj0Y4Un

http://www.minyanville.com/business-news/politics-and-regulation/articles/asco-pfizer-johnson-2526-johnson-ariad/5/15/2012/id/41024